glp 1 and insulin resistance GLP-1 Agonist Effects on Glucagon Suppression The Role of Glp-1 Receptor

The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide) has been further updated to highlight the potential risk of severe acute pancreatitis with these products, including rare reports of necrotising and fatal pancreatitis

GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential use in treating alcohol use disorder.

The potential biological mechanisms underlying their influence on cancer risk are complex, involving metabolic regulation, direct antitumor effects, immune modulation, and epigenetic changes

Fair editorial context for readers

Compounding pharmacies and investors have brought legal challenges to enjoin the FDA from enforcing the changes to the shortage list, but have so far been unsuccessful